| Revenue growth | FY26 3.6%; Q4FY26 1.3% |
|---|---|
| Margins | Targeting 8-8.5% UCP margins despite commodity pressure. |
| Order book | Carried forward order book grew 10.5% to ₹6,923 Cr. |
| Demand visibility | Strong summer demand pick-up from mid-April 2026. |
| Management confidence | Cautiously optimistic for FY27 despite input cost headwinds. |
Growth
FY26 Consolidated Revenue up 3.6%; EBITDA grew 6.2% to ₹930.4 Cr; Unitary Products Q4 revenue grew 1.3%.
Outlook
Targets 15% RAC market share; projected FY27 industry growth of 18-20%; annual capex ₹250-350 Cr.
Risks
Geopolitical uncertainty (war), rising input costs (copper, plastics), and supply chain disruptions due to Middle East crisis.
Earnings Call filed with NSE, NSE: BLUESTARCO. Summary written with AI assistance from the document.
Blue Star Ltd: key numbers
- Share price
- ₹1,565.00
- Market cap
- ₹32,179 Cr
- Revenue (annual)
- ₹12,402 Cr
- Net profit (annual)
- ₹527.7 Cr
- P/E (TTM)
- 63.2×Sector 45.9×
- Promoter holding
- 36.50%+0.01% QoQ
- FII holding
- 12.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Blue Star Ltd
All →Blue Star Annual General Meeting
Blue Star Limited has issued a Postal Ballot notice seeking shareholder approval for the appointment of Mr. Nikhilesh Panchal as an Independent Director.
Blue Star Legal & Regulatory
Blue Star Limited informed that W.J. Towell & Co LLC has filed an annulment petition in the Dubai Court of Appeal challenging a prior favourable arbitration award.
Blue Star Debt & Borrowing: ₹100 Cr
Blue Star Limited has fixed September 18, 2026, as the record date for its listed Commercial Paper. The maturity amount for this security is Rs. 100 Crores.
- Value
- ₹100.0 Cr
Blue Star Merger & Restructuring Worth ₹40 Cr
Blue Star Limited completed the slump sale of its MedTech division, housed under subsidiary Blue Star E&E, to Cyrix Healthcare for Rs 40 Crore.
- Value
- ₹40.00 Cr
Blue Star Earnings Call Transcript: Key Takeaways
Blue Star missed margin expectations significantly due to inability to pass on commodity costs and a delayed summer. While revenue grew 13%, operational performance was hit by high-cost inventory and aggressive discounting to maintain market share.
- Call
- Guides 18% growth
Blue Star Investor Presentation: Key Takeaways
Blue Star reported Q1FY27 revenue growth of 13% YoY to ₹3378 cr, but EBITDA and PBT declined significantly due to rising input costs and weak commercial refrigeration demand.